TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB | Delayed Deutsche Boerse AG 03:39:57 2024-06-10 pm EDT | ||
| 13.67 EUR | +0.44% |
|
| Current month | +2.40% | ||
| 1 month | +10.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 13.67 | +0.44% |
| 24-06-07 | 13.61 | +1.26% |
| 24-06-06 | 13.44 | +4.84% |
| 24-06-05 | 12.82 | -4.68% |
| 24-06-04 | 13.45 | +0.75% |
Delayed Quote Deutsche Boerse AG
Last update June 10, 2024 at 03:39 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW88X1 |
| ISIN | DE000SW88X18 |
| Date issued | 2024-04-19 |
| Strike | 2,931 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 12.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.93 € |
|---|---|
| Lowest since issue | 11.75 € |
| Spread | 0.3 € |
| Spread % | 2.16% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,922
DKK
Average target price
2,464
DKK
Spread / Average Target
+28.17%
- Stock Market
- Certificates
- Certificat
